Nobles Medical Technologies II Receives Allowance of Its Groundbreaking Patent for Next-Generation Suturing Device

FOUNTAIN VALLEY, CA.,  Nobles Medical Technologies II (NMT2) today announced that it has received notice of allowance of its claims for its next-generation suturing technology. With the issuance of this patent, NMT2 will expand its suture technologies to include the ability to remotely perform a running suture. This technology will be applied to NMT2's ASD-closure project currently under development.

Prof. Anthony Nobles, CEO of NMT2 and co-inventor on the allowed patent claims, commented, "This technology, which is currently under the working title NobleStitch™ QP, is completely different than our previous interrupted-suturing technology. The QP will allow us to place surgical patches and perform running sutures to close Atrial Septal Defects (ASD). ASD and Trans-Septal punctures are a priority for us at NMT2 as we have grown our international PFO business."

Ben Brosch, President of NMT2 and co-inventor on the allowed patent claims, commented, "This is another example of our commitment to intellectual property, as well as our vision to keep expanding the resources of NMT2 to provide solutions for both PFO and ASD closure. It also comes just after our recent success of First-In-Man of a NobleStitch ASD closure, as well as Septal Aneurysm repair." 

Rich Babcock, a Director of NMT2, stated, "I continue to be amazed at the concentrated progress a small group of talented inventors can make in such a short period of time. In my many years of representing startups and entrepreneurs, I have never seen an inventor achieve as many strong patents as Prof. Nobles. NobleStitch™ QP continues to demonstrate his prowess in this field, and his essential contribution to NMT2 and its shareholders." 

Source: Nobles Medical Technology